...
首页> 外文期刊>Molecular medicine reports >Effect of Salvia miltiorrhiza and ligustrazine injection on myocardial ischemia/reperfusion and hypoxia/reoxygenation injury
【24h】

Effect of Salvia miltiorrhiza and ligustrazine injection on myocardial ischemia/reperfusion and hypoxia/reoxygenation injury

机译:丹参和川li嗪注射液对心肌缺血/再灌注和缺氧/复氧损伤的影响

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Salvia miltiorrhiza and ligustrazine are traditional Chinese medicines that have been used in combination for treatment of cardiovascular disease, including coronary heart disease, cardiac angina and atherosclerosis in Asia, in particular, China. The present study aimed to determine the effect of S. miltiorrhiza and ligustrazine injection (SLI) on myocardial ischemia/reperfusion (I/R) and hypoxia/reoxygenation (H/R) injuries via the Akt serine/threonine kinase (Akt)-endothelial nitric oxide synthase (eNOS) signaling pathway. Male Sprague-Dawley rats were randomly assigned into six groups: i) Sham group; ii) I/R group; iii) Low-SLI group (6.8 mg/kg/day, i.p.); iv) Medium-SLI group (20.4 mg/kg/day, i.p.); v) High-SLI group (61.2 mg/kg/day, i.p.); vi) verapamil group (6 mg/kg/day, i.p.). Prior to surgery, the aforementioned groups were pretreated with a homologous drug once per day for 3 days. The effect of SLI following 35 min coronary artery occlusion and 2 h reperfusion was evaluated by determining infarct size, hemodynamics, biochemical values and histological observations. Additionally, cell viability, caspase-3 expression, B cell leukemia/lymphoma-2 (Bcl-2)/Bcl-2-associated X protein (Bax) ratio, phosphorylated (p-) Akt and p-eNOS were also investigated following 2 h simulated ischemia and 2 h simulated reperfusion in H9C2 cardiomyocyte cells. Pretreatment with SLI significantly improved cardiac function in a dose-dependent manner and reduced myocardial infarct size, creatine kinase, lactate dehydrogenase and malondialdehyde levels in blood serum. Additionally, myocardial histopathology changes in the rat model were also alleviated in SLI treatment groups. The present in vitro study revealed that treatment with SLI reduced the apoptotic rate of H9C2 cells by inhibiting the activation of caspase-3 and increasing the Bcl-2/Bax ratio. The effect of SLI was associated with increased phosphorylation of the survival kinase Akt at Ser473 and its downstream target eNOS following H/R. The present study determined that SLI may alleviate I/R injury in cardiomyocytes and inhibit apoptosis in rats by the activation of the Akt-eNOS signaling pathway, and downregulation of the expression levels of proapoptotic factors, including caspase-3.
机译:丹参和川gust嗪是传统的中药,在亚洲尤其是中国,已被组合用于治疗心血管疾病,包括冠心病,心绞痛和动脉粥样硬化。本研究旨在确定通过Akt丝氨酸/苏氨酸激酶(Akt)-内皮对S. miltiorrhiza和Ligustrazine注射液(SLI)对心肌缺血/再灌注(I / R)和缺氧/复氧(H / R)损伤的影响一氧化氮合酶(eNOS)信号传导途径。将雄性Sprague-Dawley大鼠随机分为六组:i)假手术组; ii)I / R组; iii)低SLI组(6.8 mg / kg /天,腹腔注射); iv)中SLI组(20.4 mg / kg /天,腹腔注射); v)高SLI组(61.2 mg / kg /天,i.p.); vi)维拉帕米组(6 mg / kg /天,腹膜内)。在手术之前,上述组每天用同源药物预处理一次,共3天。通过确定梗死面积,血流动力学,生化值和组织学观察,评估35分钟冠状动脉闭塞和2 h再灌注后SLI的效果。此外,还研究了细胞活力,caspase-3表达,B细胞白血病/淋巴瘤2(Bcl-2)/ Bcl-2相关X蛋白(Bax)比,磷酸化(p-)Akt和p-eNOS。 h9H2心肌细胞中的模拟缺血和2h模拟再灌注。 SLI预处理以剂量依赖性方式显着改善心脏功能,并降低血清中的心肌梗塞面积,肌酸激酶,乳酸脱氢酶和丙二醛水平。另外,在SLI治疗组中,大鼠模型中的心肌组织病理学改变也得到缓解。目前的体外研究表明,SLI处理可通过抑制caspase-3的激活并增加Bcl-2 / Bax的比例来降低H9C2细胞的凋亡率。 SLI的作用与H / R后Ser473处的生存激酶Akt及其下游靶标eNOS磷酸化增加有关。本研究确定,SLI可以通过激活Akt-eNOS信号通路和下调包括caspase-3在内的凋亡因子的表达水平来减轻心肌细胞的I / R损伤并抑制大鼠的细胞凋亡。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号